Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a medicine called Fosmanogepix for treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This Phase 3 study compares Fosmanogepix with standard treatments to see if it works at least as well as current therapies. The trial involves adult patients diagnosed with these infections, aiming to assess treatment success and patient survival. Participants receive one of two treatments two-thirds get Fosmanogepix through an intravenous IV infusion daily at the clinic, with an option to switch to oral tablets if well enough to continue treatment at home. One-third receive the standard care of Caspofungin IV infusion followed by oral Fluconazole capsules. Matching placebos are used for blinding. Treatment can last up to 6 weeks depending on infection clearance and symptom improvement. During the study, participants undergo regular assessments including blood tests and monitoring for treatment success and safety. Researchers measure survival at 30 days and response rates at multiple time points, including after treatment ends and at a 6-week follow-up. The study tracks adverse events, lab abnormalities, and drug levels to evaluate safety and treatment effects. Total participation can last up to about 12.5 weeks with follow-up visits to monitor long-term outcomes.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.
Actively Recruiting
This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of ianalumab in adolescents and adults with systemic lupus erythematosus who have previously completed treatment in one of two core SIRIUS-SLE studies. This extension study focuses on participants with moderate-to-severe disease activity and positive anti-nuclear antibodies. The study is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. The study involves three treatment periods over up to 7 years a 3-year double-blind phase where participants receive ianalumab subcutaneously either monthly or quarterly, or a monthly placebo followed by a 2-year period assessing safety and efficacy of treatment withdrawal and open-label monthly ianalumab and finally, an open-label safety monitoring period lasting up to 2 years. Participants receive the treatments subcutaneously as scheduled during each period. Participants will be closely monitored throughout the study, with assessments covering adverse events, disease activity responses, damage indices, corticosteroid use, and antibody levels. The primary measure is the number of treatment-emergent adverse events or serious adverse events up to about 324 weeks. Regular evaluations include clinical assessments, laboratory tests, and serum measurements. The total study duration for participants may extend up to 7 years, including long-term safety follow-up.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole compared to co-trimoxazole alone for treating Pneumocystis pneumonia PCP in adults living with HIV. The study is a Phase 2, open-label, randomized trial designed to expand knowledge about the clinical use of rezafungin in this population. Participants are adults diagnosed with definitive, presumptive, or clinically suspected PCP and living with HIV. The study includes a Screening period from Day -2 to Day -1, a Treatment period from Day 1 to Day 21, and a Follow-up visit around Day 50. Participants are randomly assigned to one of two groups one group receives weekly intravenous rezafungin infusions on Days 1, 8, and 15 combined with 7 days of oral or IV co-trimoxazole, while the other group receives co-trimoxazole alone for 21 days. Dosing adjustments for co-trimoxazole are made for participants with reduced kidney function. After the treatment period, all participants receive secondary prophylaxis against PCP following local guidelines. Throughout the study, participants will be monitored for adverse events and treatment response, including the rates of PCP relapse or immune reconstitution inflammatory syndrome. Safety assessments include vital signs, laboratory tests blood counts, chemistry, urinalysis, physical exams, and heart monitoring with ECGs. Medication use will be recorded. The total participation duration is approximately 52 days, ending with a follow-up visit to evaluate outcomes and safety.